Avita Medical Ltd (RCEL)
NASDAQ:RCEL
Want to see RCEL full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.29Last Year’s EPS
-0.38Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented multiple positive operational and commercial developments: sequential and year-over-year revenue growth, reduced operating expenses, improving net loss, RECELL reimbursement normalization, encouraging Cohealyx clinical data, BARDA partnership, and a credit facility structured with meaningful covenant headroom. Offsetting these positives are margin pressure from product mix and inventory reserves, a seasonal cash burn with a modest cash balance, and the early-stage commercialization risk of Cohealyx and PermeaDerm requiring further adoption and data to realize scale. Overall, the company appears to be transitioning from stabilization to execution with tangible early momentum but still faces near-term cash and margin headwinds as new products scale.Company Guidance
Revenue Growth and Momentum
Total revenue of ~$19.3M in Q1 2026, up ~4% year-over-year and ~10% sequentially (Q1 vs Q4 2025); highest quarterly revenue in the past year and momentum continuing into April.
Operating Expense Reduction
Total operating expenses of $24.5M, down 11% year-over-year, reflecting cost-saving actions and a stabilized, lower cost base aligned with current scale.
Improved Net Loss
Net loss of $10.6M ($0.35 per share) vs $13.9M ($0.53 per share) in the prior year period — an improvement of ~23.7% in dollars.
Strong Gross Dollars and RECELL Margin
Overall gross margin of 81.7% (down from 84.7% prior year due to mix), with RECELL gross margin remaining strong at ~85%; newer products contribute incremental gross dollars and are accretive in absolute terms.
Clinical Momentum for Cohealyx
Interim Cohealyx-I data showing a significant reduction in time to graft readiness (~20 days vs benchmark) and median time to grafting of ~11 days, with some cases achieving grafting within the first week and positive investigator satisfaction supporting early adoption.
RECELL Reimbursement Normalization and Product Expansion
All 7 Medicare Administrative Contractors have published payment rates, leading to a gradual return to procedure-driven utilization; expansion into smaller burns with RECELL GO mini and recent regulatory clearances in Australia and New Zealand.
Strategic Government Partnership (BARDA)
New long-term BARDA agreement supports U.S. burn emergency preparedness with up to $25.5M potential revenue and ~$3.9M guaranteed over 10 years (~$100k per quarter), providing modest recurring readiness revenue and validation of scalability.
Improved Commercial Cadence and Forecastability
Shift to more frequent, smaller orders and better alignment between usage and purchasing across core accounts, enabling more consistent, predictable demand and weekly forecasting cadence.
Balance Sheet and Credit Facility Alignment
Ended Q1 with ~$14.3M in cash and marketable securities; new Perceptive Advisors credit facility with lower covenants and minimum cash requirements provides headroom (example: $69M trailing 12-month revenue covenant implies only ~$15M quarterly revenue requirement).
RCEL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RCEL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2026 | $4.36 | $4.56 | +4.59% |
Feb 12, 2026 | $3.72 | $4.16 | +11.83% |
Nov 06, 2025 | $3.40 | $3.77 | +10.88% |
Aug 07, 2025 | $5.38 | $4.25 | -21.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Avita Medical Ltd (RCEL) report earnings?
Avita Medical Ltd (RCEL) is schdueled to report earning on Aug 06, 2026, Before Open (Confirmed).
What is Avita Medical Ltd (RCEL) earnings time?
Avita Medical Ltd (RCEL) earnings time is at Aug 06, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RCEL EPS forecast?
RCEL EPS forecast for the fiscal quarter 2026 (Q2) is -0.29.